Market Overview

U.K. Government Rejects GW Pharmaceuticals PLC's Cannabis Drug

Share:

On Wednesday, U.K.-based media reported that a cannabis drug developed by GW Pharmaceuticals PLC (NASDAQ: GWPH) has been rejected by the National Institute For Health and Care Excellence (NICE).

The government body is tasked with determining suitable medicines for use within England's state health service. GW Pharmaceuticals produces Sativex, a cannabis-based drug that is sprayed under a patient's tongue for treating spasticity in multiple sclerosis.

GW Pharmaceuticals sells Sativex as a prescription drug within the U.K. by its partner, German group Bayer, and is approved for use in more than 20 countries.

Related Link: Brochstein: Marijuana Rapidly Developing Into A Real Industry

NICE determined that use of the drug does not provide value for the state health system. Paul Cooper, a consultant neurologist at the Greater Manchester Neuroscience Centre said that, “there are better ways to improve care for people with MS.”

"We think it is a terrible shame that, because of cost-cutting presented as science, MS patients in England are being denied a treatment which works in many cases," a GW Pharmaceutical spokesman said. "It is sad that it should be put out of the reach of many patients in the very county where it was developed."

In addition to Sativex, NICE has also rejected non-cannabis based drugs, including Fampyra which is sold in the United States by Biogen.

Shares of GW were down 2.2 percent at $77.99.

Posted-In: Canabis GW Pharmaceuticals SavitexNews Health Care Global General

 

Related Articles (GWPH)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Royal Dutch Shell PLC Buyback Of Own Shares Update

Kathy Weidman Joins Rovi As Senior VP And General Manager, Metadata